An antibody that boosts muscle mass could mean independence for the frail and elderly. Learn how Novartis research aims to improve healthy aging.
Ann Aerts has stared death in the eye. The head of the non-profit Novartis Foundation lost colleagues when she was serving as an emergency medicine physician on a medical mission in a dangerously unstable country.
The head of Public Affairs for the Novartis Malaria Initiative has a malaria story of her own to tell.
Ricardo Dolmetsch was living the scientific dream by his mid-30s. Already a professor at Stanford University, he was running a successful lab, winning grants and receiving recognition for work in an area of neuroscience called calcium channel signaling. But then his son was diagnosed with autism.
The cause of a rare, inherited, often fatal kidney disease in many patients remained elusive for years, despite multiple attempts to solve the mystery. Then in 2012, a team of researchers cracked some of the unsolved cases in just six weeks.
Drawing on the wealth of available data about human biology and genomics, as well as the in-house expertise of a global network of researchers, NIBR has developed new and important therapies.
To raise awareness of the sudden and profound impact of meningococcal disease on families across the globe, world-renowned photographer Anne Geddes has joined forces with the Confederation of Meningitis Organizations (CoMO) and Novartis Vaccines and Diagnostics for the Protecting Our Tomorrows: Portraits of Meningococcal Disease project.
Today, many companies are trying to solve global health challenges through philanthropy. However, it has become clear that philanthropy alone is no longer enough to make a lasting impact.
Using new technologies, researchers have developed a deeper understanding of how cells function, changing conceptions of disease.
University students majoring in the life sciences or business often have trouble imagining the direction of their careers.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.